Last reviewed · How we verify
Evolocumab or Alirocumab — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Evolocumab or Alirocumab (Evolocumab or Alirocumab) — Rigshospitalet, Denmark.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Evolocumab or Alirocumab TARGET | Evolocumab or Alirocumab | Rigshospitalet, Denmark | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Evolocumab or Alirocumab CI watch — RSS
- Evolocumab or Alirocumab CI watch — Atom
- Evolocumab or Alirocumab CI watch — JSON
- Evolocumab or Alirocumab alone — RSS
Cite this brief
Drug Landscape (2026). Evolocumab or Alirocumab — Competitive Intelligence Brief. https://druglandscape.com/ci/evolocumab-or-alirocumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab